Double-blind, Randomized, Controlled Trial of EPI-743 in Friedreich’s Ataxia. Neurodegnerative Disease Management, Theresa A. Zesiewicz, Jason Salemi, Susan Perlman, Kelly L. Sullivan, Jessica D. Shaw, Yangxin Huang, Charles Isaacs, Clifton Gooch, David Lynch, Matthew B. Klein
Kelly L. Sullivan

EPI-743 (Alpha-Tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich’s Ataxia, Theresa A. Zesiewicz, Susan Perlman, Kelly L. Sullivan, Yangxin Huang, Jason L. Salemi, Matthew Klein, Charles Isaacs, Clifton Gooch, Jessica Shaw, David Lynch
Kelly L. Sullivan

Double-blind, Randomized, Controlled Trial of EPI-743 in Friedreich’s Ataxia. Neurodegnerative Disease Management, Theresa A. Zesiewicz, Jason Salemi, Susan Perlman, Kelly L. Sullivan, Jessica D. Shaw, Yangxin Huang, Charles Isaacs, Clifton Gooch, David Lynch, Matthew B. Klein
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications

EPI-743 (Alpha-Tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich’s Ataxia, Theresa A. Zesiewicz, Susan Perlman, Kelly L. Sullivan, Yangxin Huang, Jason L. Salemi, Matthew Klein, Charles Isaacs, Clifton Gooch, Jessica Shaw, David Lynch
Department of Biostatistics, Epidemiology, and Environmental Health Sciences Faculty Publications